Clifford Swan Investment Counsel LLC Has $16.93 Million Stock Position in Bristol Myers Squibb Company $BMY

Clifford Swan Investment Counsel LLC cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 293,833 shares of the biopharmaceutical company’s stock after selling 7,632 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Bristol Myers Squibb were worth $16,931,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth about $25,000. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $27,000. Bayban bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on BMY. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Wednesday, August 5th. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. Finally, Truist Financial reissued a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Stock Up 0.5%

Shares of NYSE:BMY opened at $66.93 on Tuesday. The firm has a market cap of $136.72 billion, a P/E ratio of 14.74, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The business has a fifty day simple moving average of $62.01 and a 200 day simple moving average of $59.72. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.